Adicet Bio Inc
USUSDAdicet Bio Inc (US:ACET) — Biotechnology: Pharmaceutical Preparations. Aantal beurzen waarop de aandelen van het bedrijf worden verhandeld: 2. Op deze pagina — koers en grafiek, dividenden, grootste aandeelhouders en historiek van het aantal aandelen.
Over het bedrijf
- Website
- adicetbio.com
- Beleggersrelaties
- adicetbio.com/investors/
- Sector
- Health Care · Biotechnology: Pharmaceutical Preparations
- Hoofdkantoor
- BOSTON, United States
- CEO
- Chen Schor
- Werknemers
- 102
- Uitstaande aandelen
- 9.36 mln. per 2026-08-03
- Free float
- 7.43 mln.
- Marktkapitalisatie
- 52.52 mln. USD
- Insiders
- 1.08%
- Institutionele beleggers
- 64.72%
- Branche (SIC)
- Pharmaceutical Preparations
- FCF
- −85.0 mln. USD
- Schuld
- 0
- Winst en FCF — voor de 12 maanden tot 30.06.2026 (het laatste rapport van het bedrijf).
Beschrijving
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
Nieuws deze week
Nog geen nieuws van de website van het bedrijf.
Grootste aandeelhouders
| Houder | Belang | Aandelen | Rapportdatum |
|---|---|---|---|
| RA Capital Management, L… | 9.96% | 932 624 | 2026-06-30 |
| Orbimed Advisors LLC. | 9.02% | 844 787 | 2026-06-30 |
| Franklin Resources, Inc. | 6.69% | 626 571 | 2026-06-30 |
| Citadel Advisors Llc | 4.62% | 432 738 | 2026-06-30 |
| Vanguard Capital Managem… | 3.67% | 343 228 | 2026-06-30 |
| Adage Capital Partners G… | 2.93% | 274 375 | 2026-06-30 |
| Renaissance Technologies… | 2.84% | 265 945 | 2026-06-30 |
| Stonepine Capital Manage… | 2.62% | 245 518 | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.57% | 240 946 | 2026-06-30 |
| Franklin Strategic Serie… | 2.41% | 225 186 | 2026-07-31 |
| Alyeska Investment Group… | 2.18% | 203 799 | 2026-06-30 |
| Schonfeld Strategic Advi… | 2.09% | 195 514 | 2026-06-30 |
| KLICKSTEIN LLOYD (Direct… | ≈1.16% | 108 566 | 2025-06-11 |
| VANGUARD INDEX FUNDS-Van… | 1.06% | 98 912 | 2026-06-30 |
| Bridgeway Funds, Inc.-Ul… | 0.92% | 85 959 | 2026-06-30 |
| Fidelity Concord Street… | 0.45% | 42 111 | 2026-07-31 |
| iShares Trust-iShares Mi… | 0.25% | 23 781 | 2026-08-31 |
| DUBIN STEVE (Director) | ≈0.24% | 22 700 | 2025-06-11 |
| Fidelity Concord Street… | 0.19% | 17 349 | 2026-07-31 |
| CHODAKEWITZ JEFFREY A. M… | ≈0.19% | 17 700 | 2025-06-11 |
| SINCLAIR ANDREW (Directo… | ≈0.19% | 17 700 | 2025-06-11 |
| Dimensional ETF Trust-Di… | 0.16% | 14 520 | 2026-07-31 |
| DFA INVESTMENT DIMENSION… | 0.15% | 14 264 | 2026-07-31 |
| Fidelity Concord Street… | 0.13% | 12 361 | 2026-07-31 |
| PENG KATIE (Director) | ≈0.13% | 11 800 | 2025-06-11 |
| ORBIMED ADVISORS, L.L.C.… | — | — | 2026-04-08 |
